Skip to content

Esperion Therapeutics ESPR Convertible Preferred Stock Authorized Shares

Convertible Preferred Stock Authorized Shares at other companies

Lexicon Pharmaceuticals logo
Lexicon PharmaceuticalsLXRX
5B0.0%
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
10M
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
10M0.0%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
10M0.0%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
5M0.0%
BridgeBio Pharma logo
BridgeBio PharmaBBIO

Other financials

Income statement

See full
Revenue$80.1M+23.2%
Operating income-$6.6M+70.2%
Net income-$25.2M+37.7%
EPS (diluted)-$0.10+52.4%

Balance sheet

See full
Cash & equivalents$156.2M+36.2%
Total debt$155.2M+6.1%
Total equity-$307.9M+27.8%
Total assets$462.5M+42.7%

Cash flow

See full
Operating cash flow-$27.7M-22.5%
CapEx$189.0K
Free cash flow-$27.9M-23.3%

Valuation

See full
Market cap$811.73M+283%
Enterprise value$810.81M+233%
P/S1.9×+1.1×

Profitability

See full
Operating margin18.1%+12.7pp
Net margin-34.8%+8.0pp
FCF margin-30.7%

Returns & leverage

See full
Return on equity-260.8%
Debt / equity0.8×
Current ratio1.5×+0.4×

Where this comes from

Reported directly by Esperion Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockSharesAuthorized.

The official record: Esperion Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Esperion Therapeutics's convertible preferred stock authorized shares.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Esperion Therapeutics's convertible preferred stock authorized shares?
Esperion Therapeutics (ESPR) reported convertible preferred stock authorized shares of 5M in Q1 2026.
How has Esperion Therapeutics's convertible preferred stock authorized shares changed year-over-year?
Esperion Therapeutics's convertible preferred stock authorized shares decreased by 0.0% year-over-year, from 5M to 5M.
What is the long-term trend for Esperion Therapeutics's convertible preferred stock authorized shares?
Over 5 years (2020 to 2025), Esperion Therapeutics's convertible preferred stock authorized shares has grown at a 0.0% compound annual growth rate (CAGR), from 5M to 5M.
What does convertible preferred stock authorized shares mean?
Maximum number of convertible preferred shares the company is authorized to issue under its corporate charter.